Covered recipient · General Payments record
RYAN KLEIN
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$36,805.74
184 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,155.00 | 13 |
| Food and Beverage | $3,233.21 | 158 |
| Travel and Lodging | $1,967.53 | 12 |
| Honoraria | $450.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RYAN KLEIN
NPI 1184620866 · CMS profile ID 144056
Allopathic & Osteopathic Physicians / Internal Medicine
NEWPORT BEACH, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RYAN KLEIN, NPI 1184620866, CMS profile ID 144056. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). RYAN KLEIN, NPI 1184620866, CMS profile ID 144056. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- RYAN KLEIN, NPI 1184620866, CMS profile ID 144056, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184620866?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
184 matching records · $36,805.74 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 184.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $4.79 | 05/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673799341 | CMS |
| GlaxoSmithKline, LLC. | $24.83 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670988301 | CMS |
| GlaxoSmithKline, LLC. | $0.66 | 05/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670342023 | CMS |
| GlaxoSmithKline, LLC. | $0.62 | 05/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670726368 | CMS |
| GlaxoSmithKline, LLC. | $10.38 | 05/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671410373 | CMS |
| Janssen Pharmaceuticals, Inc | $15.40 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658850461 | CMS |
| Astellas Pharma US Inc | $17.72 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655640267 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4.60 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700465871 | CMS |
| PFIZER INC. | $4.18 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673802413 | CMS |
| GENZYME CORPORATION | $24.86 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694001063 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.91 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687417255 | CMS |
| Grifols USA, LLC | $5.86 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692586319 | CMS |
| Amgen Inc. | $20.16 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662984651 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.88 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700465873 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.49 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685644485 | CMS |
| GlaxoSmithKline, LLC. | $6.65 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670717735 | CMS |
| Novartis Pharmaceuticals Corporation | $18.76 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659693833 | CMS |
| GlaxoSmithKline, LLC. | $24.88 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671217611 | CMS |
| Grifols USA, LLC | $16.27 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692583969 | CMS |
| Astellas Pharma US Inc | $23.26 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655640263 | CMS |
| Sunovion Pharmaceuticals Inc. | $15.30 | 04/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161433 | CMS |
| Sunovion Pharmaceuticals Inc. | $50.00 | 04/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161453 | CMS |
| Sunovion Pharmaceuticals Inc. | $2,280.00 | 04/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161431 | CMS |
| Sunovion Pharmaceuticals Inc. | $21.64 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161435 | CMS |
| Sunovion Pharmaceuticals Inc. | $50.41 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161439 | CMS |
| Sunovion Pharmaceuticals Inc. | $56.40 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161441 | CMS |
| Sunovion Pharmaceuticals Inc. | $252.42 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161449 | CMS |
| Sunovion Pharmaceuticals Inc. | $58.46 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161437 | CMS |
| Sunovion Pharmaceuticals Inc. | $75.00 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161443 | CMS |
| Sunovion Pharmaceuticals Inc. | $90.00 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161445 | CMS |
| Sunovion Pharmaceuticals Inc. | $103.98 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161447 | CMS |
| Sunovion Pharmaceuticals Inc. | $379.60 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688161451 | CMS |
| Genentech USA, Inc. | $21.51 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681312631 | CMS |
| Aytu BioScience, Inc | $13.28 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668008715 | CMS |
| GlaxoSmithKline, LLC. | $11.60 | 04/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670344755 | CMS |
| PFIZER INC. | $11.63 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673801279 | CMS |
| GlaxoSmithKline, LLC. | $3,600.00 | 03/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671433065 | CMS |
| Janssen Pharmaceuticals, Inc | $12.62 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658850359 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.94 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687417253 | CMS |
| Mylan Specialty L.P. | $16.78 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694779761 | CMS |
| Amgen Inc. | $23.92 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662984667 | CMS |
| GlaxoSmithKline, LLC. | $107.19 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670563191 | CMS |
| Merck Sharp & Dohme Corporation | $17.98 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695357359 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4.74 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700465875 | CMS |
| GENZYME CORPORATION | $24.30 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693988453 | CMS |
| GlaxoSmithKline, LLC. | $16.56 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671555835 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.30 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700465877 | CMS |
| Philips Electronics North America Corporation | $18.06 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684070017 | CMS |
| GlaxoSmithKline, LLC. | $2.75 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671474389 | CMS |
| Regeneron Pharmaceuticals, Inc. | $81.47 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673507251 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,561,622.39 | 318 |
| PY2024 | Principal investigator | $961,837.56 | 314 |
| PY2023 | Principal investigator | $617,104.05 | 80 |
| PY2022 | Principal investigator | $616,975.34 | 88 |
| PY2021 | Principal investigator | $392,976.03 | 62 |
| PY2020 | Principal investigator | $296,194.85 | 43 |
| PY2019 | Principal investigator | $480,642.80 | 52 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
318 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $144.41 | 12/31/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552215 |
| Principal investigator 1 | United Therapeutics Corporation | $1,641.60 | 12/24/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386855 |
| Principal investigator 1 | United Therapeutics Corporation | $1,641.60 | 12/24/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386875 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,546.00 | 12/22/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226139131 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 12/17/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 12/17/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.32 | 12/17/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.70 | 12/17/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 12/17/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772557 |
| Principal investigator 1 | GENZYME CORPORATION | $396.00 | 12/15/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226139128 |
| Principal investigator 1 | PFIZER INC. | $13,500.00 | 12/11/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228816697 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27,891.50 | 12/09/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220791771 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14,700.00 | 12/04/2025 | Non-covered Recipient Entity Newport Native Md | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235995333 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,632.97 | 12/03/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185552251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 12/03/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 12/03/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 12/03/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623466 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 12/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772581 |
| Principal investigator 1 | United Therapeutics Corporation | $380.70 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386887 |
| Principal investigator 1 | United Therapeutics Corporation | $2,242.00 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386889 |
| Principal investigator 1 | United Therapeutics Corporation | $3,005.10 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386893 |
| Principal investigator 1 | United Therapeutics Corporation | $3,341.25 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386895 |
| Principal investigator 1 | United Therapeutics Corporation | $11,848.95 | 12/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 11/26/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/26/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/26/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772575 |
| Principal investigator 1 | United Therapeutics Corporation | $1,468.80 | 11/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386853 |
| Principal investigator 1 | United Therapeutics Corporation | $1,134.00 | 11/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386869 |
| Principal investigator 1 | United Therapeutics Corporation | $1,468.80 | 11/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 11/25/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 11/25/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 11/25/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 11/25/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 11/25/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772513 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,812.00 | 11/24/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226139123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 11/20/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 11/20/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 11/20/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 11/20/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 11/20/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 11/19/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.64 | 11/19/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 11/19/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772547 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,178.20 | 11/14/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185552255 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,273.20 | 11/12/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791765 |
| Principal investigator 1 | United Therapeutics Corporation | $4,838.40 | 11/12/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386863 |
| Principal investigator 1 | United Therapeutics Corporation | $4,838.40 | 11/12/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386885 |
| Principal investigator 1 | United Therapeutics Corporation | $7,932.60 | 11/12/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 11/07/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 11/07/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 11/07/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 11/07/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 11/07/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772493 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,393.97 | 11/06/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192173968 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,032.90 | 11/05/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192178780 |
| Principal investigator 1 | Incyte Corporation | $290.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560776 |
| Principal investigator 1 | Incyte Corporation | $793.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560782 |
| Principal investigator 1 | Incyte Corporation | $375.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560786 |
| Principal investigator 1 | Incyte Corporation | $1,240.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560794 |
| Principal investigator 1 | Incyte Corporation | $4,720.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560801 |
| Principal investigator 1 | Incyte Corporation | $430.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560807 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 11/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560812 |
| Principal investigator 1 | Insmed, Inc. | $1,352.25 | 11/03/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 11/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 11/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 11/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623462 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772525 |
| Principal investigator 1 | AstraZeneca UK Limited | $15,313.94 | 10/27/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185552225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $373.12 | 10/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $693.50 | 10/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.56 | 10/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 10/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.00 | 10/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772541 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,753.32 | 10/23/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192174941 |
| Principal investigator 1 | Insmed, Inc. | $7,206.17 | 10/22/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646006 |
| Principal investigator 1 | GENZYME CORPORATION | $7,825.00 | 10/20/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226139114 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,677.00 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185552241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.11 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,459.05 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.11 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,459.05 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,502.08 | 10/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251279 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,800.17 | 10/15/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185552233 |
| Principal investigator 1 | Genentech, Inc. | $15,861.00 | 10/15/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211629002 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,304.50 | 10/14/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791763 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,801.14 | 10/10/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 | No dispute reported | 06/30/2026 | 1185552245 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $28,908.35 | 10/10/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185552257 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,746.00 | 10/08/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192178757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 10/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 10/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 10/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 09/24/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $766.50 | 09/24/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.48 | 09/24/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.00 | 09/24/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772473 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,664.68 | 09/24/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192177708 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,000.00 | 09/22/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226139098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,916.38 | 09/19/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184240886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.00 | 09/19/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184240888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,067.27 | 09/19/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184240890 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $51,730.99 | 09/18/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192174933 |
| Principal investigator 1 | United Therapeutics Corporation | $29,146.50 | 09/10/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386865 |
| Principal investigator 1 | United Therapeutics Corporation | $2,106.00 | 09/10/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.01 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.01 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 09/08/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.09 | 09/04/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.79 | 09/04/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.17 | 09/04/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.62 | 09/04/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 09/04/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772483 |
| Principal investigator 1 | Genentech, Inc. | $10,296.00 | 09/03/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211628994 |
| Principal investigator 1 | Insmed, Inc. | $5,535.75 | 09/02/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646000 |
| Principal investigator 1 | Insmed, Inc. | $400.00 | 09/02/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 09/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 09/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 09/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 09/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,067.27 | 08/22/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,916.38 | 08/22/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184229963 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,500.00 | 08/21/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220791769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,575.72 | 08/20/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192177688 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,961.68 | 08/20/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192177704 |
| Principal investigator 1 | United Therapeutics Corporation | $13,697.10 | 08/06/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386905 |
| Principal investigator 1 | GENZYME CORPORATION | $1,923.00 | 08/04/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226139063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 08/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 08/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 08/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772457 |
| Principal investigator 1 | Genentech, Inc. | $1,729.00 | 08/01/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211628997 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,903.00 | 08/01/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192174952 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,302.00 | 08/01/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177680 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $156.00 | 08/01/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192178761 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,445.12 | 07/23/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185552237 |
| Principal investigator 1 | AstraZeneca UK Limited | $18,500.00 | 07/18/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185552227 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $93.55 | 07/16/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192174949 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100,879.26 | 07/14/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (AirleafTM) | No dispute reported | 06/30/2026 | 1220791767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.00 | 07/14/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214868 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,968.10 | 07/11/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE) | No dispute reported | 06/30/2026 | 1185552249 |
| Principal investigator 1 | United Therapeutics Corporation | $3,110.40 | 07/08/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386861 |
| Principal investigator 1 | United Therapeutics Corporation | $3,110.40 | 07/08/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 07/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 07/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 07/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $223.56 | 07/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.00 | 06/27/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $673.00 | 06/27/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD MD INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211727 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 06/25/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645986 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 06/25/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645992 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 06/25/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645996 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 06/25/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645998 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 06/24/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623430 |
| Principal investigator 1 | Incyte Corporation | $1,607.40 | 06/18/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560714 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,439.95 | 06/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 1192177699 |
| Principal investigator 1 | GENZYME CORPORATION | $8,724.00 | 06/16/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226139015 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $66.76 | 06/16/2025 | Non-covered Recipient Entity Newportnativemd Inc | A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps | No dispute reported | 06/30/2026 | 1226139008 |
| Principal investigator 1 | Genentech, Inc. | $15,050.00 | 06/13/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211628991 |
| Principal investigator 1 | United Therapeutics Corporation | $2,592.00 | 06/11/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386859 |
| Principal investigator 1 | United Therapeutics Corporation | $2,592.00 | 06/11/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386881 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.96 | 06/05/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791761 |
| Principal investigator 1 | Incyte Corporation | $24.78 | 06/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560718 |
| Principal investigator 1 | Incyte Corporation | $8.64 | 06/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560733 |
| Principal investigator 1 | Incyte Corporation | $3.84 | 06/03/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 06/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 06/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 06/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 06/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772429 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $601.47 | 05/28/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 | No dispute reported | 06/30/2026 | 1185552223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.90 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 05/27/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772443 |
| Principal investigator 1 | GENZYME CORPORATION | $396.00 | 05/27/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138998 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,376.66 | 05/22/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192174945 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,780.00 | 05/16/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192178776 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $57,599.47 | 05/13/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185552231 |
| Principal investigator 1 | GENZYME CORPORATION | $5,358.00 | 05/12/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138994 |
| Principal investigator 1 | United Therapeutics Corporation | $205.20 | 05/07/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386847 |
| Principal investigator 1 | United Therapeutics Corporation | $1,468.80 | 05/07/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386851 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,220.40 | 05/05/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177692 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560692 |
| Principal investigator 1 | Incyte Corporation | $251.42 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560697 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560701 |
| Principal investigator 1 | Incyte Corporation | $57.81 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560708 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560744 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560755 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560761 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 05/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 05/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623420 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 05/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623422 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 05/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 05/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 05/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 05/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $799.00 | 05/01/2025 | Non-covered Recipient Entity Huntington Beach Internal Medicine Group | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220772431 |
| Principal investigator 1 | Insmed, Inc. | $11,481.40 | 04/30/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645984 |
| Principal investigator 1 | Insmed, Inc. | $0.66 | 04/30/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645988 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 04/30/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645990 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 04/30/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645994 |
| Principal investigator 1 | United Therapeutics Corporation | $1,468.80 | 04/23/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386871 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,664.67 | 04/17/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192174937 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,672.00 | 04/16/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome | No dispute reported | 06/30/2026 | 1185552259 |
| Principal investigator 1 | Incyte Corporation | $1,607.40 | 04/14/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560687 |
| Principal investigator 1 | United Therapeutics Corporation | $864.00 | 04/09/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386849 |
| Principal investigator 1 | United Therapeutics Corporation | $864.00 | 04/09/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386867 |
| Principal investigator 1 | AstraZeneca UK Limited | $665.58 | 04/08/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185552239 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 04/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560726 |
| Principal investigator 1 | Incyte Corporation | $57.85 | 04/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 04/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 04/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 04/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623418 |
| Principal investigator 1 | GENZYME CORPORATION | $3,364.00 | 03/24/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138943 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,825.00 | 03/21/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192178748 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,595.00 | 03/21/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192178766 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,600.80 | 03/17/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791759 |
| Principal investigator 1 | Incyte Corporation | $2,469.00 | 03/14/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560582 |
| Principal investigator 1 | Incyte Corporation | $1,975.20 | 03/14/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560681 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,550.00 | 03/12/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) | No dispute reported | 06/30/2026 | 1185552219 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,952.50 | 03/10/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791757 |
| Principal investigator 1 | Genentech, Inc. | $892.00 | 03/07/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211628986 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,297.74 | 03/06/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | No dispute reported | 06/30/2026 | 1192177685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 03/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 03/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 03/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623400 |
| Principal investigator 1 | United Therapeutics Corporation | $205.20 | 02/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386841 |
| Principal investigator 1 | United Therapeutics Corporation | $1,728.00 | 02/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386857 |
| Principal investigator 1 | United Therapeutics Corporation | $1,728.00 | 02/26/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 02/25/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623406 |
| Principal investigator 1 | GENZYME CORPORATION | $990.00 | 02/24/2025 | Non-covered Recipient Entity Newportnativemd Inc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138947 |
| Principal investigator 1 | Insmed, Inc. | $1,121.45 | 02/21/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645978 |
| Principal investigator 1 | Insmed, Inc. | $230.85 | 02/21/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645980 |
| Principal investigator 1 | Insmed, Inc. | $157.95 | 02/21/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645982 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,500.00 | 02/20/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | No dispute reported | 06/30/2026 | 1192173964 |
| Principal investigator 1 | Incyte Corporation | $1,072.80 | 02/19/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560617 |
| Principal investigator 1 | Incyte Corporation | $1,805.00 | 02/19/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560624 |
| Principal investigator 1 | Incyte Corporation | $1,856.00 | 02/19/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560632 |
| Principal investigator 1 | Incyte Corporation | $1,856.00 | 02/19/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560637 |
| Principal investigator 1 | United Therapeutics Corporation | $2,851.20 | 02/12/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386843 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,400.00 | 02/10/2025 | Non-covered Recipient Entity Newportnativemd Inc | A randomized, double-blind, placebo-controlled, parallel-group, 52-week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately-controlled chronic rhinosinusitis with nasal polyps | No dispute reported | 06/30/2026 | 1226138955 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $751.00 | 02/07/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192174957 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $751.00 | 02/07/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192177713 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,500.00 | 02/06/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192174928 |
| Principal investigator 1 | Insmed, Inc. | $0.88 | 02/05/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645958 |
| Principal investigator 1 | Insmed, Inc. | $16,073.96 | 02/05/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645962 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 02/05/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645966 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 02/05/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 02/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 02/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 02/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623394 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,070.57 | 01/31/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT | No dispute reported | 06/30/2026 | 1185552229 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $31,846.86 | 01/29/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1185552243 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,980.16 | 01/29/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA | No dispute reported | 06/30/2026 | 1185552247 |
| Principal investigator 1 | United Therapeutics Corporation | $2,851.20 | 01/29/2025 | Non-covered Recipient Entity NewportNativeMD Inc | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242386845 |
| Principal investigator 1 | United Therapeutics Corporation | $10,652.85 | 01/29/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386899 |
| Principal investigator 1 | Amgen Inc. | $27,793.59 | 01/27/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1246645290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 01/27/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.82 | 01/27/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623404 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,606.30 | 01/27/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791755 |
| Principal investigator 1 | Insmed, Inc. | $15,000.00 | 01/24/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645974 |
| Principal investigator 1 | Insmed, Inc. | $1,500.00 | 01/24/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645976 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $224,234.45 | 01/17/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | No dispute reported | 06/30/2026 | 1185552217 |
| Principal investigator 1 | Incyte Corporation | $1,805.00 | 01/17/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560607 |
| Principal investigator 1 | Incyte Corporation | $1,444.00 | 01/17/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560613 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $61,081.34 | 01/15/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185552221 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,149.80 | 01/13/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192178771 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,136.47 | 01/09/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD INC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192178752 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,959.68 | 01/08/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase III Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma | No dispute reported | 06/30/2026 | 1185552235 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645960 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645964 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645968 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189645970 |
| Principal investigator 1 | United Therapeutics Corporation | $2,898.00 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386891 |
| Principal investigator 1 | United Therapeutics Corporation | $11,000.00 | 01/08/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242386901 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,279.90 | 01/06/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220791753 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,887.55 | 01/03/2025 | Non-covered Recipient Entity NEWPORTNATIVEMD, INC. | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185552253 |
| Principal investigator 1 | Incyte Corporation | $46.08 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560588 |
| Principal investigator 1 | Incyte Corporation | $10.78 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560601 |
| Principal investigator 1 | Incyte Corporation | $57.81 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560643 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560651 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560658 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560664 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560671 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity NEWPORT NATIVE MD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240560676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 01/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 01/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $194.99 | 01/01/2025 | Non-covered Recipient Entity NewportNativeMD Inc | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220623416 |